On February 14, covid-19 pharmaceutical concept stocks strengthened, Porton Pharma Solutions Ltd(300363) , Aba Chemicals Corporation(300261) , Jinghua Pharmaceutical Group Co.Ltd(002349) , senxuan medicine, Zhejiang Jianfeng Group Co.Ltd(600668) and other stocks rose by the limit, and Asymchem Laboratories (Tianjin) Co.Ltd(002821) , Wuhan Hiteck Biological Pharma Co.Ltd(300683) and other stocks rose first.
Source: choice
On the news, the State Food and Drug Administration approved the import registration of the combined packaging of nevitavir tablets / ritonavir tablets (paxlovid), a covid-19 virus treatment drug of Pfizer, with conditions on February 11.
Minsheng Securities said that China’s demand related to covid-19 virus treatment will be gradually released in the future, and pay attention to the restorative growth of relevant medical demand after the lifting of epidemic prevention measures.
Paxlovid is a combination of pf-07321332 and ritonavir. Minsheng Securities believes that paxlovid’s China has been approved to further expand the target group, and the breakthrough of domestic covid-19 medicine is imminent, which is expected to further benefit the API (active drug ingredient) industrial chain.
China Securities Journal · China Securities Taurus reporter combed Pfizer covid-19 pharmaceutical upstream industry chain related companies:
Chinese manufacturer of carbonic anhydride for synthesizing PF: Aba Chemicals Corporation(300261) and Zhejiang Jianfeng Group Co.Ltd(600668) . Among them, Aba Chemicals Corporation(300261) on January 5, it was said that the total capacity of carbonic anhydride and its derivatives was about 20 tons / month, and the recent capacity utilization rate was 70% – 80%.
Chinese manufacturers of isopentenol, the intermediate of PF synthesis : Zhejiang Nhu Company Ltd(002001) and Zhejiang Medicine Co.Ltd(600216) . In terms of production capacity, Zhejiang Nhu Company Ltd(002001) previously said on the interactive platform that the company’s annual output of isopentenol was about 10000 tons. According to the Research Report of China International Capital Corporation Limited(601995) , Zhejiang Medicine Co.Ltd(600216) isoamylenol has a production capacity of 1000 tons.
Chinese manufacturer of Pyrethroic acid, the intermediate of PF synthesis : Jiangsu Yangnong Chemical Co.Ltd(600486) .
Chinese manufacturer of ritonavir / ritonavir intermediate : Jinghua Pharmaceutical Group Co.Ltd(002349) , Wuhan Hiteck Biological Pharma Co.Ltd(300683) , Geli pharmaceutical, Northeast Pharmaceutical Group Co.Ltd(000597) . Jinghua Pharmaceutical Group Co.Ltd(002349) said that the production capacity of the intermediate of senxuan medicine ritonavir is 230 tons, and there is no API production capacity. At present, there is no authoritative survey result for the specific market share data; Wuhan Hiteck Biological Pharma Co.Ltd(300683) said on the interactive platform that the subsidiary Xiamen Weijia is mainly engaged in the production and sales of key intermediates such as ritonavir and lopinavir; Ge Li pharmaceutical said that the production capacity of ritonavir oral tablets was expanded to 100 million tablets / year; Northeast Pharmaceutical Group Co.Ltd(000597) previously said that the company currently owns the preparation method patent of ritonavir. At present, the product is still in the early stage of research and development, and there is uncertainty whether it can reach the stage of application for registration.
\u3000\u3000 CDMO: Asymchem Laboratories (Tianjin) Co.Ltd(002821) 、 Porton Pharma Solutions Ltd(300363) 、 Xi’An Manareco New Materials Co.Ltd(688550) 。 Asymchem Laboratories (Tianjin) Co.Ltd(002821) in 2021, major daily operation contracts were signed successively, with the amount of USD 481 million and RMB 2.72 billion; Porton Pharma Solutions Ltd(300363) recently announced that it received a purchase order of 681 million US dollars from Pfizer’s company; According to the semi annual report of 2021, the indication of the terminal drug corresponding to a pharmaceutical intermediate product supplied to Pfizer is covid-19 project, and the clinical progress of the terminal drug cannot be known.
Source: compiled by China Securities Taurus reporter
Minsheng Securities said that the listing and stable supply of domestic oral covid-19 drugs are expected to improve the outlook of the upstream API industry chain. At present, China has entered phase III clinical trials with real biological azvudine and Shanghai Junshi Biosciences Co.Ltd(688180) nucleoside vv116. Vv116 is the third oral covid-19 drug in the world and the first domestic drug authorized for emergency use. It is more likely to be approved for marketing in China in the future. Other domestic drugs with the same mechanism as Pfizer are currently in preclinical status. In addition, covid-19 treatment will still drive many peripheral needs, such as the application of symptomatic drugs such as hormones.
Source: Minsheng Securities Research Report
